LakeShore Biopharma Co (LakeShore Biopharma Co) Additional Paid-In Capital : $364.06 Mil(As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Additional Paid-In Capital?

LakeShore Biopharma Co's quarterly additional paid-in capital increased from Sep. 2022 ($115.20 Mil) to Mar. 2023 ($385.57 Mil) but then stayed the same from Mar. 2023 ($385.57 Mil) to Sep. 2023 ($364.06 Mil).

LakeShore Biopharma Co's annual additional paid-in capital increased from Mar. 2021 ($123.00 Mil) to Mar. 2022 ($127.43 Mil) and increased from Mar. 2022 ($127.43 Mil) to Mar. 2023 ($385.57 Mil).

LakeShore Biopharma Co Additional Paid-In Capital Historical Data

The historical data trend for LakeShore Biopharma Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Additional Paid-In Capital Chart

LakeShore Biopharma Co Annual Data

Trend

Mar21

Mar22

Mar23

Additional Paid-In Capital

123.00

127.43

385.57

LakeShore Biopharma Co Semi-Annual Data
	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Additional Paid-In Capital	Get a 7-Day Free Trial			-	127.43	115.20	385.57	364.06

LakeShore Biopharma Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

LakeShore Biopharma Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

LakeShore Biopharma Co (LakeShore Biopharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

H6Z:Germany

Address

38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629

Website

https://www.yishengbio.com

YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.